Clinical trial
A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
NCT01670994 is registered in ClinicalTrials.gov with Altor BioScience as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
- Lead sponsor
- Altor BioScience
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- August 14, 2012
- Completion date
- September 9, 2015
- Enrollment
- 6 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
relapsed or refractory multiple myeloma